PRKCQ and neuroblastoma: Consistent with data from PRKCQ‐AS1 or MSI2 knockdown, treatment with NSC617570 reduces BMX expression, ERK protein phosphorylation, neuroblastoma cell proliferation and clonogenic capacity.